H.C. Wainwright analyst Patrick Trucchio maintains $Sangamo Therapeutics (SGMO.US)$ with a buy rating, and maintains the target price at $10.
According to TipRanks data, the analyst has a success rate of 31.5% and a total average return of -0.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sangamo Therapeutics (SGMO.US)$'s main analysts recently are as follows:
Following the announcement that Pfizer will not proceed with a Biologics License Application for giroctocogene fitelparvovec, a gene therapy candidate for moderately severe to severe hemophilia A, Sangamo was notably taken aback. Despite the surprising turn of events, there remains significant potential for Sangamo in the treatment of Fabry, even under conservative estimates for the project's success.
The analyst notes that the return of Sangamo's hemophilia A program by Pfizer, just prior to the anticipated biologics license application filing, was unexpected. This action means Sangamo misses out on potential regulatory and first-sales milestones amounting to $220M, which increases the funding pressures on Sangamo. The company's current cash reserves are expected to support its operations until the first quarter of 2025, and efforts are underway to partner its Fabry gene therapy program to extend its financial runway.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
H.C. Wainwright分析師Patrick Trucchio維持$Sangamo Therapeutics (SGMO.US)$買入評級，維持目標價10美元。
根據TipRanks數據顯示，該分析師近一年總勝率為31.5%，總平均回報率為-0.5%。
此外，綜合報道，$Sangamo Therapeutics (SGMO.US)$近期主要分析師觀點如下：
輝瑞宣佈不會繼續處理giroctogene fitelparvovec的生物製劑許可申請（一種治療中重度至重度甲型血友病的基因療法），此後，桑加莫大吃一驚。儘管事態發生了令人驚訝的轉折，但即使對該項目成功的保守估計，桑加莫在治療法布瑞方面仍有巨大的潛力。
分析師指出，在預期的生物製劑許可證申請提交之前，輝瑞恢復了桑加莫的A型血友病項目，這出乎意料。這一行動意味着Sangamo錯過了總額爲2.2億美元的潛在監管和首次銷售里程碑，這增加了Sangamo的資金壓力。該公司目前的現金儲備預計將在2025年第一季度之前支持其運營，並且正在努力與其Fabry基因療法計劃合作，以延長其財務狀況。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
